Summary of Edwards Lifesciences Conference Call Company Overview - **Company**: Edwards Lifesciences (NYSE: EW) - **Industry**: Medical Technology, specifically focusing on heart valve therapies and surgical solutions Key Points and Arguments TAVR (Transcatheter Aortic Valve Replacement) - **Clinical Data Impact**: The presentation of EARLY TAVR clinical trial data in late 2024 significantly boosted confidence in the durability of the SAPIEN valve family, leading to increased business momentum in 2025 [3][4] - **Growth Drivers**: The second half of 2025 saw a 10.6% growth in U.S. TAVR, attributed to increased urgency in treating severe aortic stenosis, driven by new clinical data [9][10] - **2026 Growth Guidance**: Projected TAVR growth of 6%-8% for 2026, with confidence in this guidance due to a global footprint of approximately 2,000 sites performing SAPIEN procedures [11][12] - **NCD and Guidelines**: Upcoming National Coverage Determination (NCD) and updates to U.S. guidelines are critical for future TAVR performance [14][15] TMTT (Transcatheter Mitral and Tricuspid Therapies) - **Portfolio Expansion**: For the first time, Edwards offers both repair and replacement solutions for mitral and tricuspid regurgitation, enhancing its position as a partner for physicians [5][24] - **Market Dynamics**: The TMTT market is growing, with PASCAL being the current revenue leader, while EVOQUE is growing at a faster rate [26][27] - **Clinical Trials**: Upcoming clinical trial data, such as CLASP II TR and TRISCEND II, are expected to provide insights into the performance of PASCAL and EVOQUE [29][30] Surgical Innovations - **New Solutions**: Edwards is preparing to introduce a left atrial appendage (LAA) closure solution, complementing its existing surgical portfolio [47][48] - **Investment in Surgical**: Continued investment in surgical innovations reflects the company's commitment to expanding its offerings in valvular disease treatment [48] Financial Performance - **Gross Margin Guidance**: Expected gross profit margin of 78%-79% for 2026, with operating profit margin projected to grow by 150 basis points [51] - **R&D Investments**: R&D as a percentage of sales is expected to decrease from 19.4% in 2024 to around 17% in 2026, indicating a focus on efficiency while driving innovation [53][54] Capital Allocation and M&A Strategy - **External Investments**: Edwards is open to external investments, focusing on early-stage technologies that complement internal innovations in structural heart [55][56] Innovation Focus - **Core Strategy**: The company emphasizes the importance of innovation as the foundation of its culture and business strategy, aiming to maintain leadership in the structural heart market [57] Additional Important Insights - **Physician Engagement**: The company is focused on improving treatment rates for patients with mitral and tricuspid regurgitation, rather than merely capturing market share [26] - **Patient Outcomes**: Positive anecdotal evidence from patients treated with EVOQUE highlights the significant impact of the therapy on quality of life [32] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, providing a comprehensive overview of the company's current position and future outlook in the medical technology industry.

Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]

Core Insights - Edwards Lifesciences Corporation is positioned for growth due to its innovative Surgical Structural Heart segment and the successful TAVR platform, despite facing macroeconomic challenges and litigation expenses [1][8]. Business Performance - The Surgical Structural Heart segment grew by 5.3% year-over-year in Q3 2025, driven by the adoption of RESILIA tissue and technologies like INSPIRIS, MITRIS, and KONECT [3][4]. - The TAVR business experienced a 10.6% year-over-year growth in Q3 2025, supported by stable pricing and competitive positioning [5][6]. - The TMTT segment saw a remarkable 53% increase in sales in Q3 2025, fueled by the performance of PASCAL and EVOQUE systems [9][10]. Market Position - Edwards Lifesciences has a market capitalization of $48.33 billion and has outperformed the industry with a 13.4% stock increase over the past year, compared to a 2.1% decline in the industry [2]. - The company has consistently surpassed earnings estimates, achieving an average surprise of 8.89% over the last four quarters [2]. Challenges - The company faces macroeconomic pressures, including a 31.3% increase in cost of goods sold (COGS) due to inflation and supply chain issues [11]. - Ongoing litigation related to patent rights poses risks to the company's growth and reputation [12]. Future Outlook - The Zacks Consensus Estimate for Edwards Lifesciences' 2025 earnings per share (EPS) is $2.59, with projected revenues of $6.03 billion, indicating a 1% increase from the previous year [13].

Edwards Lifesciences 2025 Investor Conference 2025 Investor Conference Mark Wilterding Cautionary Statement Presentations and comments made today by management of Edwards Lifesciences Corporation (the "Company") will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can sometimes be identified by the use of words, such as "may," "will," "should," ...